Company Description
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.
It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
The company was founded in 2009 and is headquartered in Westminster, Colorado.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Mary Szela |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado 80031 United States | |
| Phone | (888) 321-5212 |
| Website | trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 89680M101 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President and Director |
| Jodi Devlin | Chief of Clinical Strategy and Operations |
| David B. Patience | Chief Financial Officer |
| Lori Ann Santamaria | Vice President of Operations |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Chief Commercial Officer |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
| James E. Young | Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 4, 2025 | SCHEDULE 13D/A | Filing |
| Aug 1, 2025 | SCHEDULE 13D/A | Filing |
| Jul 25, 2025 | SC TO-I/A | Filing |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 22, 2025 | EFFECT | Notice of Effectiveness |
| Jul 15, 2025 | SC TO-I/A | Filing |